Eli Lilly and Company (VIE:LLYC)

Austria · Delayed Price · Currency is EUR

871.50

+3.80 (0.44%)

At close: Dec 5, 2025

9.58% (1Y)

Market Cap	777.61B
Revenue (ttm)	50.64B
Net Income (ttm)	15.69B
Shares Out	n/a
EPS (ttm)	17.42
PE Ratio	49.55
Forward PE	32.00
Dividend	5.35 (0.62%)
Ex-Dividend Date	Nov 14, 2025

Volume	29
Average Volume	79
Open	871.10
Previous Close	867.70
Day's Range	870.50 - 878.60
52-Week Range	539.10 - 965.00
Beta	n/a
RSI	53.13
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Industry Pharmaceutical Preparations

Founded 1876

Employees 47,000

Stock Exchange Vienna Stock Exchange

Ticker Symbol LLYC

Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

There is no news available yet.